TheraRadar
← Back
Data updated: Jun 28, 2026

AKARX INC

Pharma
Pharmaceuticals

AKARX INC is a pharmaceutical company with 2 FDA-approved products.

2018
Since
2
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
2 Small Molecules

FDA Novel Drug Designations

(2018)
1 Novel 1 Priority Review
See 1 novel approval →
2018 DOPTELET (AVATROMBOPAG MALEATE) Priority Review

AKARX INC's Key Drugs

AKARX INC's core commercial portfolio centers on DOPTELET, DOPTELET SPRINKLE — its most strategically important drugs approved in the last 15 years.

DOPTELET
Hepatology

Thrombocytopenia

TPO receptor Approved 2018
DOPTELET SPRINKLE
Hepatology

Thrombocytopenia

TPO receptor Approved 2025

AKARX INC's Recent FDA Approvals

AKARX INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

DOPTELET SPRINKLE NDA
2025-07-24
avatrombopag maleate
Thrombocytopenia

AKARX INC's Therapeutic Areas

Disease areas where AKARX INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

AKARX INC Pipeline Snapshot

Active clinical trials for AKARX INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • DOPTELET leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling